The final, formatted version of the article will be published soon.
EDITORIAL article
Front. Microbiol.
Sec. Infectious Agents and Disease
Volume 15 - 2024 |
doi: 10.3389/fmicb.2024.1537105
This article is part of the Research Topic Recent advances in the prevention, diagnosis and treatment of Chagas Disease View all 7 articles
Editorial: The challenges for the diagnosis and treatment of Chagas disease
Provisionally accepted- Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
Chagas disease (CD), also known as American trypanosomiasis, is caused by the parasite Trypanosoma cruzi. It is prevalent in areas belonging to South and Central America, but in the global scenario, the disease ranks third among parasitic diseases (World Health Organization, 2023).Currently, it is estimated that around 10 million people are infected worldwide, especially in Latin America, where the disease is endemic and is the leading cause of non-ischemic heart disease (Pan American Health Organization, 2023). T. cruzi is mainly transmitted by kissing bugs hematophagous insects belonging to the subfamily Triatominae. Thus, CD stands out as a public health problem in Latin America and other continents, mainly in North America and Europe. This spread is due to the immigration of infected individuals and the expansion of the insect vector in border areas, in addition to the failure to control clinical procedures such as blood transfusions and organ transplants (Nunes et al., 2018). Another form of transmission is the congenital form. Congenital infection with T. cruzi has become the primary mode of CD transmission in non-endemic countries where pregnant women are not regularly screened for the infection (Antinori et al., 2017). At the maternal-fetal interface, a complex interaction takes place between the parasite and host cells when bloodstream trypomastigotes engage with the syncytiotrophoblasts (SYNs) ( Despite the availability of some drugs in the clinic, these therapies have significant limitations. 58The toxicity associated with available medications, especially nifurtimox and benznidazole, often 59 limits treatment adherence, given the adverse effects of continued use (Ferri et al., 2023;Gonzaga et 60 al., 2023). Although such treatment shows results in the acute phase of the disease, its effectiveness in
Keywords: Trypanosomatids, New therapeutic strategies, Chagas disease diagnosis, Chagas Disease, Trypanosoma cruzi
Received: 29 Nov 2024; Accepted: 03 Dec 2024.
Copyright: © 2024 Frechiani, Vieyra and Dick. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Claudia Dick, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.